Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study
I'm LongbridgeAI, I can summarize articles.Alpha Tau Medical reported strong clinical data for its Alpha DaRT therapy combined with Keytruda in head and neck cancer, showing a 100% objective response rate. The company is advancing this pipeline across multiple cancer types. While analysts maintain a Buy rating with a $15 target, TipRanks' AI assigns a Neutral score due to weak financials, including no revenue and cash burn, despite positive technical signals.
Alpha Tau Medical Ltd ( (DRTS) ) has provided an announcement.
Alpha Tau Medical Ltd., a Jerusalem-based developer of the Alpha DaRT alpha-radiation cancer therapy, is advancing a pipeline across head and neck, skin, pancreatic, prostate and brain cancers. Listed on Nasdaq under DRTS and DRTSW, the company is seeking to establish Alpha DaRT in localized unresectable tumors and in metastatic disease alongside checkpoint inhibitors.
On July 21, 2026, Alpha Tau reported clinical data showing a 100% objective response rate and 18.2-month median overall survival in nine evaluable elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma treated with Alpha DaRT plus pembrolizumab. The single-center study exceeded its pre-specified success threshold, showed no serious Alpha DaRT-related adverse events, and delivered outcomes that compare favorably to historical pembrolizumab monotherapy, bolstering Alpha Tau’s combination strategy and supporting further, larger trials that could enhance its position in the immuno-oncology treatment landscape.
The most recent analyst rating on (DRTS) stock is a Buy
with a $15.00 price target.
To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock,
see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, widening losses, and significant ongoing cash burn) and limited valuation support (negative P/E, no dividend yield provided). This is partially offset by constructive technical trend signals, with the stock trading above its 20/50/100/200-day moving averages.
To see Spark’s full report on DRTS stock,
click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israel-based oncology company developing Alpha DaRT, an alpha-radiation therapy for solid tumors. The Nasdaq-listed firm focuses on head and neck, skin, pancreatic, prostate and brain cancers, targeting elderly and frail patients who may not tolerate aggressive chemotherapy and aiming to position Alpha DaRT alongside leading immunotherapies.
The company’s clinical strategy emphasizes both localized unresectable disease and metastatic settings, using Alpha DaRT as a potentially immune-activating radiotherapy. Its growing pipeline and collaborations with leading cancer centers underpin efforts to integrate Alpha DaRT into standard-of-care regimens and expand its global market presence.
Average Trading Volume: 918,855
Technical Sentiment Signal: Buy
Current Market Cap: $1.19B